Coronary disease & ACSRandomised controlled trial
Colchicine in Acute Myocardial Infarction
- Randomised controlled trial
- multicentre
- 2-by-2 factorial
Vital status unknown for 45 patients (0.6%), most likely missing at random
Authors' conclusion
Among patients who had myocardial infarction, treatment with colchicine, when started soon after myocardial infarction and continued for a median of 3 years, did not reduce the incidence of the composite primary outcome (death from cardiovascular causes, recurrent myocardial infarction, stroke, or unplanned ischemia-driven coronary revascularization).
Study context
- Population
- Patients who had MI
- Participants
- 7,062 patients · 104 centres · 14 countries
- Comparison
- Colchicine vs placebo
- Colchicinen = 3,528
- Placebon = 3,534reference
- Primary endpoint
- Composite of:
- CV death
- Recurrent MI
- Stroke
- Unplanned ischemia-driven coronary revascularization (time-to-event)
- Follow-up
- Median 3 years
Primary result
As reported in the abstract
median 3 years
Hazard ratio
0.99
95% CI 0.85–1.16
P = 0.93
Events by treatment group
Colchicine vs Placebo
HR 0.99 (95% CI 0.85–1.16); P = 0.93
Further findings
| Outcome | least-squares mean difference (mg per liter) (95% CI) | |
|---|---|---|
| C-reactive protein (subgroup) · 3 months · adjusted for baseline values | −1.28 (−1.81 to −0.75) | |
| −2−101Difference, mg per liter (linear scale) |
Individual components of the primary outcome
- Appeared to be similar in the two groups
Safety
Diarrhea
P < 0.001
Serious infections
- Did not differ between groups
Original publication
Colchicine in Acute Myocardial Infarction. N Engl J Med. Published 17 November 2024. doi:10.1056/nejmoa2405922
Summarised from the published abstract; every number is checked against it